Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

ICT01 Plus Azacitidine and Venetoclax Shows Early Evidence of Antitumor Activity in AML

April 29th 2025

A low dose of ICT01 added to combination therapy with azacitidine and venetoclax proved active and safe as frontline therapy in patients with AML.

Dr Cecchini on the Efficacy of Neoadjuvant Chemotherapy in CRC Liver Metastases

April 29th 2025

Michael Cecchini, MD, discusses the effects of neoadjuvant chemotherapy on tumor-infiltrating lymphocyte levels in colorectal cancer with liver metastases.

Dr Hanna on Elraglusib Plus Chemotherapy and Immunotherapy in Advanced Salivary Gland Cancer

April 29th 2025

Glenn J. Hanna, MD, discusses the efficacy of elraglusib plus chemotherapy with or without immunotherapy in patients with advanced salivary gland cancer.

Neoadjuvant Dostarlimab Eradicates Disease in 82% of Mismatch Repair–Deficient Solid Tumors

April 29th 2025

Eighty percent of patients with early-stage dMMR solid tumors given neoadjuvant dostarlimab underwent nonoperative management of their disease.

TMPRSS2-ERG Shows Distinct Molecular Landscape in TALAPRO-2 Population With mCRPC

April 28th 2025

Patients with mCRPC enrolled in the phase 3 TALAPRO-2 trial harboring TMPRSS2-ERG fusions in ctDNA had a distinct tumor molecular profile vs those without.

Talazoparib Plus Enzalutamide Improves rPFS Regardless of AR Alteration Status in mCRPC

April 28th 2025

Talazoparib plus enzalutamide improved rPFS vs placebo plus enzalutamide in patients with mCRPC with or without AR alterations.

Olaparib Plus Pembrolizumab Shows Efficacy in HRR Gene–Mutated Advanced Tumors With/Without HRD Positivity

April 27th 2025

Olaparib plus pembrolizumab was safe and effective in HRR gene–mutated and/or HRD-positive advanced tumors.

Zoldonrasib Shows Encouraging Early Antitumor Activity in KRAS G12D–Mutated NSCLC

April 27th 2025

Zoldonrasib demonstrates early promise in patients with KRAS G12D–mutated non–small cell lung cancer.

TAR-200 Produces Unprecedented CR Rates in BCG-Unresponsive, High-Risk NMIBC

April 26th 2025

TAR-200 showed promising results in treating patients with BCG-unresponsive, high-risk NMIBC, achieving an 82.4% complete response rate.

MRD Assessment Informs RFS Outcomes With Cretostimogene Grenadenorepvec in BCG-Unresponsive NMIBC

April 26th 2025

Twelve-month RFS was associated with MRD status in patients with BCG-unresponsive, NMIBC who received treatment with cretostimogene grenadenorepvec.

FDA Approval of Cabozantinib for Pancreatic and Extra-Pancreatic Neuroendocrine Tumors Opens the Door to a New Standard Option

April 25th 2025

Jennifer Chan, MD, MPH, highlights the significance of the FDA approval of cabozantinib for the treatment of patients with pNET and epNET.

Oncology Experts Preview Top Abstracts From AUA 2025

April 24th 2025

Experts highlight the top presentations to watch for at the 2025 AUA Annual Meeting.

Deintensification of Treatment Modalities Is Crucial to Consider in Head and Neck Cancer

April 24th 2025

Zafar Sayed, MD, explains advances in surgical head and neck cancer approaches, including the use of transoral robotic surgery.

Extended Adjuvant Pyrotinib Shows Promising Efficacy After Trastuzumab-Based Therapy in HER2+ Breast Cancer

April 23rd 2025

Pyrotinib led to high 2-year iDFS rates in the adjuvant setting following adjuvant trastuzumab-based treatment in HER2-positive breast cancer.

Nivolumab/Ipilimumab Establishes Unprecedented Efficacy and Safety Standards in Advanced HCC

April 23rd 2025

Aiwu Ruth He, MD, PhD, discusses data from the CheckMate 9DW trial that supported the FDA approval of frontline nivolumab plus ipilimumab for advanced HCC.

Early ESR1 Mutation Detection via ctDNA Monitoring Could Enhance Treatment Adaptation in HR+ Breast Cancer

April 21st 2025

Sara M. Tolaney, MD, MPH, discusses the value of incorporating ctDNA monitoring of ESR1 mutations into routine management for HR-positive breast cancer.

Novel Adjuvant Strategies Reshape HER2+ Breast Cancer Treatment

April 21st 2025

Paolo Tarantino, MD, discusses adjuvant strategies, trial data, and risk stratification shaping HER2+ breast cancer care.

Orthopedic Oncology Experts Shape Global Consensus on Chondrosarcoma Management

April 19th 2025

R. Lor Randall, MD, FACS, discusses the importance of orthopedic oncology consensus meetings and the need for agreement about certain surgical practices.

Cilta-Cel Emerges as a SOC in Lenalidomide-Refractory Multiple Myeloma

April 18th 2025

María-Victoria Mateos, MD, PhD, discusses data from the long-term update of CARTITUDE-4 she presented during the 51st Annual EBMT Meeting.

Dostarlimab/Chemo Earns Expanded Canadian Approval in Primary Advanced, First Recurrent Endometrial Cancer

April 18th 2025

Dostarlimab/chemotherapy was granted an expanded approval by Health Canada to treat patients with primary advanced or first recurrent endometrial cancer.